Patent ID: 9193955
Filing Date: 2015-11-24
Classification: A61K,A61P,C07K,C12N,C12Q,G01N

Abstract:
1. A method for classification of an acute myeloid leukemia (AML) according to AML stem cells (AMLSC) present, where greater percentage of AMLSC is indicative of a more aggressive cancer phenotype, the method comprising: contacting a patient sample selected from blood, bone marrow and cerebrospinal fluid, from a human patient having AML, with antibodies specific for CD34 and CD38, and an antibody or antibodies specific for one or more differentially expressed markers selected from: CD97, CD99, CD180 and TIM3; quantitating by flow cytometry the number of CD34 comparing the determined percentage to a reference, to generate a classification of the AML from the patient; and providing the classification to the patient, wherein the patient is treated for AML in accordance with the classification.